liminal biosciences inc’s stock lmnl soared 91 in premarket trade wednesday after the company said it’s received an unsolicited takeover offer of 750 a share from structured alpha lp that company already owns 64 of the outstanding stock and is now bidding for the rest the stock closed tuesday at 362 liminal specializes in discovering and developing novel and distinctive small molecule therapeutics to treat metabolic inflammatory and fibrotic diseases the board will review the offer and has formed a special committee of independent directors